

## **Asthma and the Risk of SARS-CoV-2 Infection Among Children and Adolescents**

Saahithi Rao, BA<sup>1</sup>, Jillian H. Hurst, PhD<sup>2,3</sup>, Congwen Zhao, MS<sup>1</sup>, Benjamin A. Goldstein, PhD<sup>1,3,4</sup>, Laine Thomas, PhD<sup>1,4</sup>, Jason E. Lang, MD, MPH<sup>2,4,5</sup>, Matthew S. Kelly, MD, MPH<sup>2</sup>

<sup>1</sup>Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC

<sup>2</sup>Department of Pediatrics, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC

<sup>3</sup>Department of Pediatrics, Children's Health & Discovery Initiative, Duke University School of Medicine, Durham, NC

<sup>4</sup>Duke Clinical Research Institute, Duke University, Durham, NC

<sup>5</sup>Department of Pediatrics, Division of Pulmonary and Sleep Medicine, Duke University School of Medicine, Durham, NC

**Keywords:** COVID-19; pediatrics; respiratory virus; inhaled corticosteroids; propensity score matching

**Corresponding Author:** Matthew S. Kelly, MD, MPH

2301 Erwin Rd Durham, NC 27710

Phone: 919-684-6335

Email: [matthew.kelly@duke.edu](mailto:matthew.kelly@duke.edu)

**Funding:** This project was supported by the Translating Duke Health Children's Health & Discovery Initiative and grants from the National Heart, Lung, and Blood Institute (5R21HL145415-02) and the National Center for Advancing Translational Sciences (UL1TR001117). MSK was supported by a National Institutes of Health Career Development Award (K23-AI135090).

**Financial Disclosures:** MSK reports advisory board feeds from Adagio Therapeutics, Inc and Merck & Co, Inc. All other authors have no competing interests to declare.

**Conflicts of Interest:** The authors have indicated they have no potential conflicts of interest to disclose.

**Word Count:** 2,985

## ABSTRACT

**Importance:** More than 4 million SARS-CoV-2 infections have occurred among children and adolescents in the United States. Risk factors for SARS-CoV-2 infection among children remain poorly defined.

**Objective:** To evaluate the association between asthma and the risk of SARS-CoV-2 infection among children.

**Design:** Retrospective cohort study

**Setting:** A large, integrated health system in central North Carolina.

**Participants:** Children 5 to 17 years of age with a Durham County address and at least one health care encounter in the Duke University Health System between March 1, 2017, and February 28, 2020.

**Exposure:** Diagnosis of asthma

**Main Outcomes and Measures:** The primary outcome was SARS-CoV-2 infection identified by PCR testing of a respiratory sample collected between March 1, 2020, and October 31, 2020. We matched children with asthma 1:1 to children without asthma using propensity scores and used Poisson regression to evaluate the association between asthma and the risk of SARS-CoV-2 infection. We assessed for effect modification of this association by inhaled corticosteroid prescription and comorbid atopic diseases.

**Results:** Of 49,455 children, 6,515 (13%) met criteria for a diagnosis of asthma; all children with asthma were matched to a control child without asthma for a final cohort of 13,030 children. Median (interquartile range) age was 11.0 (8.0, 14.0) years, 56% were male, and 78% were non-White. A diagnosis of asthma was associated with a decreased risk of SARS-CoV-2 infection [risk ratio (RR): 0.67, 95% confidence interval (CI): 0.49-0.92]. This association tended to be stronger in children with asthma who were prescribed inhaled corticosteroids (RR: 0.60, 95% CI: 0.38-0.94) or who had comorbid atopic diseases (RR: 0.59, 95% CI: 0.39-0.88). Of the 66 children with asthma who developed SARS-CoV-2 infection, none required hospitalization for COVID-19.

**Conclusions and Relevance:** Children with asthma had a lower risk of SARS-CoV-2 infection, particularly children prescribed an inhaled corticosteroid or with comorbid atopic diseases. Further studies are needed to explore the complex relationship between asthma, inhaled corticosteroids, and SARS-CoV-2.

## Key Points

**Question:** Does having asthma influence SARS-CoV-2 infection risk among children 5-17 years of age?

**Findings:** In this retrospective cohort study of 49,455 children, asthma was associated with a lower risk of SARS-CoV-2 infection, particularly among children with asthma who were prescribed an inhaled corticosteroid or who had comorbid atopic diseases. None of the 66 children with asthma who acquired SARS-CoV-2 required hospitalization for COVID-19.

**Meaning:** Children with asthma are at lower risk of SARS-CoV-2 infection and generally have mild SARS-CoV-2-associated illnesses. Use of inhaled corticosteroids and comorbid atopic diseases may contribute to the association between asthma and SARS-CoV-2 susceptibility.

## INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), has caused more than 185 million infections and 4 million deaths globally.<sup>1</sup> Current public health guidelines recommend that individuals with certain medical conditions, including moderate-severe asthma, take additional precautions to prevent SARS-CoV-2 infection.<sup>2,3</sup> However, several prior studies suggested that asthma may be associated with a lower susceptibility to SARS-CoV-2 infection and a low risk of severe COVID-19. In one of the first epidemiological studies of the pandemic, only 5 of 548 (<1%) patients hospitalized at Tongji Hospital in Wuhan, China had a diagnosis of asthma.<sup>4</sup> Similarly, asthmatic patients represented only 23 of 1307 (<2%) patients requiring mechanical ventilation for COVID-19 in Russia.<sup>5</sup> Similar findings were reported in studies of patients hospitalized for severe COVID-19 in Saudi Arabia and Brazil.<sup>6,7</sup> Additionally, in a retrospective study of 22,254 individuals tested for SARS-CoV-2 in New York City, asthma was less prevalent among individuals testing positive for SARS-CoV-2 compared to individuals testing negative for the virus (7% vs. 11%).<sup>8</sup> Notably, these studies focused primarily on adults and were conducted among hospitalized patients or through convenience sampling of individuals presenting for SARS-CoV-2 testing. There is an ongoing need to investigate the association between asthma and SARS-CoV-2 infection in population-based studies of children and adolescents, among whom asthma is the most common chronic medical condition and a leading cause of hospitalization.<sup>9</sup>

We sought to evaluate the risk of SARS-CoV-2 infection by asthma status in a cohort of 49,455 children receiving care in a large, integrated health system in central North Carolina. We matched 6,515 children with asthma 1:1 to children without asthma using propensity scores and evaluated the association between asthma and the risk of SARS-CoV-2 infection. As a priori-specified secondary objectives, we evaluated

the extent to which use of inhaled corticosteroids (ICS) and the presence of comorbid atopic diseases modified the association between asthma and the risk of SARS-CoV-2 infection.

## METHODS

### *Setting*

This study was conducted in the Duke University Health System (DUHS), a comprehensive medical system consisting of a large academic medical center, two community hospitals, a network of primary and urgent care clinics, and both inpatient and outpatient subspecialty services. DUHS serves as the main health care provider in Durham County, North Carolina, with an estimated 85% of Durham residents receiving care within DUHS. This study was conducted during an eight-month period from March 1, 2020 to October 31, 2020.

### *Study Population*

We identified all children 5 to 17 years of age with a Durham County address and at least one health care encounter in DUHS within the three years preceding the study period (March 1, 2017, to February 28, 2020). We classified children as having asthma if they met one of three previously validated electronic health record-based definitions during this three-year period: 1) two or more outpatient or emergency health care encounters associated with an International Classification of Diseases, Ninth/Tenth Revision (ICD-9/ICD-10) code for asthma (**Supplemental Table 1**) and an active prescription for one or more medications for asthma (**Supplemental Table 2**); 2) at least one hospital encounter associated with an ICD-9/ICD-10 for asthma and an active prescription for one of more medications for asthma; or 3) a problem list entry with an asthma-related ICD-9/ICD-10 code and an active prescription for one or more medications for asthma.<sup>10</sup>

### *Data Collection*

We used the Duke University School of Medicine Clinical Research Datamart to abstract patient data from electronic health records.<sup>11</sup> Data recorded included age, gender, race/ethnicity, insurance status, and the neighborhood deprivation index, a metric that incorporates income, education, employment, and housing quality to create scores for neighborhoods based on socioeconomic disadvantage.<sup>12</sup> To account for differences in health system engagement that could influence the likelihood of being tested for SARS-CoV-2 infection, we recorded if the child's pediatrician was within DUHS, if the child had a well-child visit in the two years prior to the study period, and the number of health care encounters in the one year preceding the study period. To identify a subset of children with asthma who were more likely to have an atopic asthma phenotype, we identified allergic rhinitis, atopic dermatitis, food allergies, and other comorbid atopic diseases using ICD-9/ICD-10 codes (**Supplemental Table 1**). SARS-CoV-2 infection was identified based on positive PCR testing of a respiratory sample obtained for clinical care.

### *Statistical Analysis*

We described characteristics of the study population by asthma status, by performance of SARS-COV-2 testing, and based upon the results of SARS-CoV-2 testing. We used Poisson regression with a sandwich variance estimator to evaluate associations between asthma, demographics, insurance type, health system engagement, and neighborhood characteristics with performance of SARS-CoV-2 testing.<sup>13</sup> We used a similar modeling approach to evaluate associations between these same factors and positive testing for SARS-CoV-2 among children who underwent one or more tests for the virus. We used logistic regression to evaluate associations between demographics, insurance type, health system engagement, and neighborhood characteristics with asthma status. The predicted covariate values from this model were then used to generate propensity scores for the probability of having asthma for all children in the dataset. We then matched each child with asthma to a single child without asthma using nearest-neighbor matching of propensity scores. Distributions of propensity scores were evaluated for balance across the



asthma and control groups (**Supplemental Figure 1**). For our primary analysis, we used Poisson regression with a sandwich variance estimator to evaluate the association between asthma status and the risk of SARS-CoV-2 infection in the propensity score-matched cohort. Finally, in a priori-specified secondary analyses, we fit modified Poisson regression models to evaluate for effect modification of the association between asthma status and SARS-CoV-2 infection by ICS prescription and comorbid atopic diseases in the propensity score-matched cohort. All statistical analyses were performed using R version 4.0.2.<sup>14</sup>

## RESULTS

### *Patient characteristics*

Of 49,455 children, 6,515 (13.2%) met the definition for asthma (**Figure 1**). Characteristics of the unmatched cohort by asthma status are shown in **Table 1**. Compared to children without asthma, children with asthma were more likely to be male (58% vs. 50%,  $p<0.001$ ), to identify as non-Hispanic Black race (55% vs. 33%,  $p<0.001$ ), and to have public insurance (57% vs. 48%,  $p<0.001$ ). Children with asthma were also more likely to have had a well-child visit within the prior two years (69% vs. 52%,  $p<0.001$ ), had more health care encounters in the preceding one year [median (interquartile range (IQR)): 2 (1, 4) vs. 1 (0, 2),  $p<0.001$ ], and were more likely to have a primary care physician in DUHS (99% vs. 97%,  $p<0.001$ ). Age and neighborhood deprivation were similar among children with and without asthma.

### *Factors associated with SARS-CoV-2 testing*

Overall, 3,594 (7.3%) children had one or more tests for SARS-CoV-2 during the study period. Children with asthma were more likely to have been tested for SARS-CoV-2 infection than children without asthma (10.4% vs. 6.8%,  $p<0.001$ ). Patient age, race/ethnicity, insurance status, and neighborhood deprivation index scores differed by SARS-CoV-2 testing status (**Table 2**). Specifically, non-Hispanic

Black race and self-pay insurance status were associated with a lower risk of being tested for SARS-CoV-2, while higher risks of being tested were observed for Hispanic ethnicity, public insurance, and higher neighborhood deprivation index scores, corresponding to higher deprivation and lower neighborhood socioeconomic status. We also observed higher levels of previous health system engagement among children who were tested for SARS-CoV-2. Compared to children who were not tested for SARS-CoV-2, tested children were more likely to have had a well-child visit in the two years preceding the study period, had more health care encounters in the year preceding the study period, and were more likely to have a primary care physician in DUHS. A total of 564 (1.1%) children tested positive for SARS-CoV-2 infection during the study period, including 66 (1.0%) children with asthma and 498 (1.2%) children without asthma. Among children tested for SARS-CoV-2 infection, non-White race, public and self-pay insurance, and higher neighborhood deprivation were associated with positive testing for SARS-CoV-2 infection (**Table 3**). One child without asthma required hospitalization for COVID-19.

#### *Association between asthma and SARS-CoV-2 infection*

We next generated propensity scores for the probability of having asthma for all children and matched each of the 6,515 children with asthma to a child without asthma using nearest-neighbor matching of propensity scores. Propensity score matching resulted in a population that was closely matched on patient characteristics (**Table 1**). Median (IQR) age was 11.0 (8.0, 14.0) years, 56% were male, and 78% were non-White. In this propensity score-matched cohort, 164 (13%) children tested positive for SARS-CoV-2 infection during the study period, including 66 (9.8%) children with asthma and 98 (16.0%) children without asthma (**Table 4**). Asthma was associated with a decreased risk of SARS-CoV-2 infection [risk ratio (RR): 0.67, 95% confidence interval (CI): 0.49–0.92]. Additionally, we found evidence of effect modification of this association by prescription of ICS and comorbid atopic disease. Specifically, children with asthma who were prescribed ICS had a lower risk of SARS-CoV-2 infection than matched control children without asthma (RR: 0.60, 95% CI: 0.38–0.94), but this association was not significant among

children with asthma who were not prescribed ICS (RR: 0.75, 95% CI: 0.49–1.15). Similarly, compared to matched control children without asthma, the risk of SARS-CoV-2 infection was lower among children with asthma and comorbid atopic diseases (RR: 0.59, 95% CI: 0.39–0.88), but not among children with asthma who did not have these conditions (RR: 0.83, 95% CI: 0.51–1.35).

## **DISCUSSION**

In this population-based study of nearly 50,000 children in central North Carolina, asthma was associated with a lower risk of acquiring SARS-CoV-2 infection. This association tended to be stronger among children with comorbid atopic diseases or concomitant ICS prescription, suggesting that these factors may contribute to the reduced susceptibility of this population to SARS-CoV-2. We identified marked differences in the likelihood of children being tested for SARS-CoV-2 by sociodemographic factors. Finally, we found no evidence that asthma predisposes children to severe COVID-19.

Few prior studies evaluated the association between asthma and susceptibility to SARS-CoV-2 infection. In a nationwide cohort study of 219,959 adults in South Korea, adults with asthma had a slightly higher risk of testing positive for SARS-CoV-2 compared with a propensity score-matched comparison group without asthma (2.3% vs. 2.2%, respectively).<sup>15</sup> In a retrospective evaluation of electronic health record data from 7,256 children tested for SARS-CoV-2 in a pediatric healthcare network in the United States, 87 of 424 (21%) children who tested positive for SARS-CoV-2 had a diagnosis of asthma, in keeping with the asthma prevalence among children in this network.<sup>16</sup> Moreover, in a study of 135,794 patients less than 25 years of age who underwent SARS-CoV-2 testing in seven pediatric health networks in the United States, children with asthma and other previously diagnosed respiratory conditions had a lower SARS-CoV-2 positivity rate.<sup>17</sup> Finally, in a community-based cohort study of 382 children and adolescents with a documented SARS-CoV-2 exposure in central North Carolina, children with asthma

were less likely to acquire the virus.<sup>18</sup> In the current study, we found that asthma was associated with a 35% lower risk of SARS-CoV-2 infection among children after accounting for differences in SARS-CoV-2 testing practices. Our findings can be used by parents, educators, and health care providers to inform decisions surrounding precautions and treatments for children with asthma.

ICS are among the medications most commonly prescribed to children with asthma.<sup>19,20</sup> Though previous research suggests that ICS use increases the risk of non-COVID-19 respiratory tract infections, the available data indicate that these medications may not increase susceptibility to and severity of SARS-CoV-2 infection.<sup>21</sup> Use of ICS for pre-existing respiratory diseases was not associated with COVID-19 severity in a study of more than 8 million adults in the United Kingdom.<sup>22</sup> Similarly, among adults in South Korea, use of ICS was not associated with COVID-19 risk and mortality.<sup>23</sup> In contrast, in the OpenSAFELY Study, adults with asthma who were prescribed high-dose ICS, but not low- or medium-dose ICS, had a higher risk of death from COVID-19.<sup>24</sup> Finally, a retrospective analysis of 928 adult patients did not identify an association between ICS use and the likelihood of testing positive for SARS-CoV-2.<sup>25</sup> Our findings suggest that ICS use may contribute to the lower risk of SARS-CoV-2 infection among children with asthma and emphasize the importance of continuing these medications during the ongoing COVID-19 pandemic.

Prior epidemiological studies have failed to demonstrate an association between asthma and COVID-19 severity. In studies conducted in adult populations, asthma has generally not been identified as a risk factor for COVID-19 severity and mortality.<sup>5,26-31</sup> Similarly, studies of children hospitalized for COVID-19 have not identified a consistent association between asthma and COVID-19 severity. Among 222 children and adolescents hospitalized with COVID-19 in the United States, 13.5% had a prior diagnosis of asthma – only slightly higher than the estimated national prevalence of asthma among children (8-10%).<sup>32</sup> In a study of 177 children with SARS-CoV-2 infection in the Washington, D.C. metro area, asthma was

not more common among children admitted to the hospital than among non-hospitalized children.<sup>33,34</sup> Similarly, in a study of 46 children hospitalized for SARS-CoV-2 infection in New York, asthma was not associated with a requirement for intensive care.<sup>35</sup> Finally, an electronic health record-based analysis of children undergoing SARS-CoV-2 testing at Children's Hospital of Philadelphia facilities found that asthma was associated with a lower odds of hospitalization for COVID-19.<sup>36</sup> In our cohort, none of the children and adolescents with asthma who were diagnosed with SARS-CoV-2 infection required hospitalization for COVID-19. Taken together, these data suggest that asthma is not associated with worse outcomes among children and adolescents with SARS-CoV-2 infection.

There are several potential mechanisms by which asthma may reduce the SARS-CoV-2 infection risk. SARS-CoV-2 entry is mediated by the cell surface proteins angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2), both of which have been demonstrated to be expressed at lower levels in individuals with asthma compared to those without asthma, though the data are conflicting regarding the levels of ACE2 and TMPRSS2 expression associated with different asthma endotypes.<sup>37-41</sup> Atopic asthma is a common endotype among children and adolescents, and is associated with excessive T-helper type-2 (Th2) responses,<sup>42,43</sup> which have been associated with lower expression of ACE2 and TMPRSS2.<sup>44,45</sup> Previous research also suggested potential mechanisms by which ICS could influence SARS-CoV-2 susceptibility. In a study of adults with chronic obstructive pulmonary disease, treatment with ICS was associated with reduced ACE2 expression, and this effect appeared to be mediated through suppression of type I interferon.<sup>46</sup> Further, the ICS ciclesonide has been shown to dampen host inflammatory responses and reduce *in vitro* replication of SARS-CoV-2 and other human coronaviruses.<sup>47</sup> Finally, the risk of SARS-CoV-2 infection might be lower among children and adolescents because of differences in behavior and risk mitigation strategies. In particular, children with asthma and other chronic respiratory diseases could have less exposure to SARS-CoV-2 than children without these chronic

conditions because of differences in perceived risk of severe COVID-19 and infection prevention or shielding practices.

The availability of SARS-CoV-2 testing to children during the COVID-19 pandemic has been influenced by national and local policies, testing availability, and our evolving understanding of the virus. Thus, the factors influencing the likelihood of being tested for SARS-CoV-2 have important implications for understanding the epidemiology of the virus and for identifying barriers to accessing health services. We found that children who identified as Hispanic ethnicity were tested at a higher rate than white children and children from other racial minority groups, but Hispanic children still had a far higher test positivity rate (32%) than other groups, highlighting the extent to which the Latinx community has been disproportionately affected by the COVID-19 pandemic in central North Carolina. We also observed that individuals with disadvantaged living conditions were tested at a higher rate and had a higher test positivity rate than individuals who lived in neighborhoods with higher socioeconomic status. Consistent with this finding, a study of children presenting for drive-up testing at an academic medical center reported that families in the highest income quartile based on census block group estimates tested positive at a lower rate than those from lower income quartiles.<sup>48</sup> Children with public insurance were both more likely to be tested for SARS-CoV-2 and had a higher SARS-CoV-2 positivity rate than children with private insurance. Taken together, these findings highlight significant disparities in SARS-CoV-2 testing accessibility and disease burden among children in central North Carolina by race/ethnicity and socioeconomic status.

Our study has several strengths and limitations. First, our cohort included more than 6,000 children with a current asthma diagnosis and active prescriptions for controller medications. While this stringent definition enabled us to have substantial confidence in the diagnosis in children classified as having asthma, children with mild asthma or who did not have active prescriptions for controller medications

were likely misclassified as not having asthma. We relied upon SARS-CoV-2 test results from within the health care system, and therefore could not account for SARS-CoV-2 testing that may have been performed at other sites. To minimize this possibility, we focused on children who reside in Durham County, for which DUHS provides the vast majority of primary and specialty pediatric services. We assumed that children who were not tested for SARS-CoV-2 did not have the virus; due to limited testing availability and asymptomatic infections, it is likely that some SARS-CoV-2 infections were not identified. We used propensity score matching to account for confounding in demographics associated with asthma and SARS-CoV-2. Finally, we were unable to account for differences in infection prevention and shielding behaviors that may have existed between asthmatic children and children without asthma.

In summary, despite the continued general precaution regarding asthma and COVID-19, we found no evidence that asthma predisposes children to SARS-CoV-2 infection or severe illness from COVID-19. We strongly recommend that children with asthma continue their treatment and asthma action plans during the ongoing COVID-19 pandemic, especially if these plans include ICS. Further research is needed to evaluate the complex relationships that exist between asthma, ICS, and SARS-CoV-2.

## References

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis*; published online Feb 19. [https://doi.org/10.1016/S1473-3099\(20\)30120-1](https://doi.org/10.1016/S1473-3099(20)30120-1).
2. Ferrante G, La Grutta S. The Burden of Pediatric Asthma. *Frontiers in Pediatrics*. 2018;6(186).
3. Centers for Disease Control and Prevention. COVID-19: People with Certain Medical Conditions. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html>. Accessed 16 July 2021.
4. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *Journal of Allergy and Clinical Immunology*. 2020;146(1):110-8.
5. Avdeev S, Moiseev S, Brovko M, Yavorovskiy A, Umbetova K, Akulkina L, et al. Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19. *Allergy*. 2020;75(10):2703-4.
6. Shabrawishi M, Al-Gethamy MM, Naser AY, Ghazawi MA, Alsharif GF, Obaid EF, et al. Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia. *PloS one*. 2020;15(8):e0237130.
7. Rezende LF, Thome B, Schweitzer MC, Souza-Júnior PRBd, Szwarcwald CL. Adults at high-risk of severe coronavirus disease-2019 (Covid-19) in Brazil. *Revista de saude publica*. 2020;54:50.
8. Marcello RK, Dolle J, Grami S, Adule R, Li Z, Tatem K, et al. Characteristics and Outcomes of COVID-19 Patients in New York City's Public Hospital System. *medRxiv*. 2020:2020.05.29.20086645.
9. Centers for Disease Control and Prevention. 2019 National Health Interview Survey data. U.S. Department of Health & Human Services. Available at: <https://www.cdc.gov/asthma/nhis/2019/data.htm>. Accessed 11 May 2021. .
10. Tang M, Goldstein BA, He J, Hurst JH, Lang JE. Performance of a computable phenotype for pediatric asthma using the problem list. *Ann Allergy Asthma Immunol*. 2020;125(5):611-3 e1.



11. Development of an electronic health records datamart to support clinical and population health research [Internet]. 2021.
12. Bonito AJ, Bann C, Eicheldinger C, Carpenter L. Creation of new race-ethnicity codes and socioeconomic status (SES) indicators for Medicare beneficiaries. RTI International, Agency for Healthcare Research and Quality. 2008.
13. Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. *American Journal of Epidemiology*. 2003;159(7):702-6.
14. R: A language and environment for statistical computing Vienna, Austria: R Foundation for Statistical Computing; 2013 [Available from: <http://www.R-project.org/>].
15. Yang JM, Koh HY, Moon SY, Yoo IK, Ha EK, You S, et al. Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. *The Journal of allergy and clinical immunology*. 2020;146(4):790-8.
16. Otto WR, Geoghegan S, Posch LC, Bell LM, Coffin SE, Sammons JS, et al. The Epidemiology of SARS-CoV-2 in a Pediatric Healthcare Network in the United States. *Journal of the Pediatric Infectious Diseases Society*. 2020.
17. Bailey LC, Razzaghi H, Burrows EK, Bunnell HT, Camacho PEF, Christakis DA, et al. Assessment of 135 794 Pediatric Patients Tested for Severe Acute Respiratory Syndrome Coronavirus 2 Across the United States. *JAMA pediatrics*. 2021;175(2):176-84.
18. Hurst JH, Heston SM, Chambers HN, Cunningham HM, Price MJ, Suarez L, et al. SARS-CoV-2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) Study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
19. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. *American Review of Respiratory Disease*. 1993;148(4\_pt\_2):S1-S26.


20. Dijkstra A, Vonk J, Jongepier H, Koppelman G, Schouten J, Ten Hacken N, et al. Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. *Thorax*. 2006;61(2):105-10.
21. Yang M, Zhang Y, Chen H, Lin J, Zeng J, Xu Z. Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis. *Infection*. 2019;47(3):377-85.
22. Aveyard P, Gao M, Lindson N, Hartmann-Boyce J, Watkinson P, Young D, et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. *The Lancet Respiratory medicine*. 2021.
23. Choi JC, Jung SY, Yoon UA, You SH, Kim MS, Baek MS, et al. Inhaled Corticosteroids and COVID-19 Risk and Mortality: A Nationwide Cohort Study. *J Clin Med*. 2020;9(11).
24. Schultze A, Walker AJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. *The Lancet Respiratory medicine*. 2020;8(11):1106-20.
25. Liao SY, Petrache I, Fingerlin TE, Maier LA. Association of inhaled and systemic corticosteroid use with Coronavirus Disease 2019 (COVID-19) test positivity in patients with chronic pulmonary diseases. *Respir Med*. 2021;176:106275.
26. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *The Journal of allergy and clinical immunology*. 2020;146(1):110-8.
27. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA : the journal of the American Medical Association*. 2020;323(13):1239-42.
28. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020;75(7):1730-41.

29. Beurnier A, Jutant EM, Jevnikar M, Boucly A, Pichon J, Preda M, et al. Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. *Eur Respir J*. 2020;56(5).
30. Pignatti P, Visca D, Cherubino F, Zampogna E, Spanevello A. Impact of COVID-19 on patients with asthma. *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease*. 2020;24(11):1217-9.
31. Chhibha KD, Patel GB, Vu THT, Chen MM, Guo A, Kudlaty E, et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. *The Journal of allergy and clinical immunology*. 2020;146(2):307-14.e4.
32. Kim L, Whitaker M, O'Halloran A, Kambhampati A, Chai SJ, Reingold A, et al. Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1-July 25, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(32):1081-8.
33. DeBiasi RL, Song X, Delaney M, Bell M, Smith K, Pershad J, et al. Severe Coronavirus Disease-2019 in Children and Young Adults in the Washington, DC, Metropolitan Region. *The Journal of pediatrics*. 2020;223:199-203.e1.
34. Akinbami LJ, Simon AE, Rossen LM. Changing trends in asthma prevalence among children. *Pediatrics*. 2016;137(1).
35. Chao JY, Derespina KR, Herold BC, Goldman DL, Aldrich M, Weingarten J, et al. Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 at a Tertiary Care Medical Center in New York City. *The Journal of pediatrics*. 2020;223:14-9.e2.
36. Floyd GC, Dudley JW, Xiao R, Feudtner C, Taquechel K, Miller K, et al. Prevalence of asthma in hospitalized and non-hospitalized children with COVID-19. *J Allergy Clin Immunol Pract*. 2021;9(5):2077-9.e2.

37. Song J, Zeng M, Wang H, Qin C, Hou H-Y, Sun Z-Y, et al. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. *Allergy*. 2020;00:1-14.
38. Camiolo M, Gauthier M, Kaminski N, Ray A, Wenzel SE. Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype. *The Journal of allergy and clinical immunology*. 2020;146(2):315-24.e7.
39. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O'Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. *J Allergy Clin Immunol*. 2020;146(1):203-6 e3.
40. Sajuthi SP, DeFord P, Jackson ND, Montgomery MT, Everman JL, Rios CL, et al. Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene expression in the airway epithelium. *bioRxiv*. 2020:2020.04.09.034454.
41. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al. COVID-19-related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids. *Am J Respir Crit Care Med*. 2020;202(1):83-90.
42. Schatz M, Rosenwasser L. The allergic asthma phenotype. *J Allergy Clin Immunol Pract*. 2014;2(6):645-8; quiz 9.
43. Kuruvilla ME, Lee FE, Lee GB. Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. *Clin Rev Allergy Immunol*. 2019;56(2):219-33.
44. Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D, Polverino F, et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. *The Journal of allergy and clinical immunology*. 2020;146(1):80-8.e8.
45. Rich HE, Antos D, Melton NR, Alcorn JF, Manni ML. Insights Into Type I and III Interferons in Asthma and Exacerbations. *Front Immunol*. 2020;11:574027.

46. Finney LJ, Glanville N, Farne H, Aniscenko J, Fenwick P, Kemp SV, et al. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. *J Allergy Clin Immunol*. 2021;147(2):510-9 e5.
47. Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et al. The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells. *Journal of virology*. 2020;95(1):e01648-20.
48. Goyal MK, Simpson JN, Boyle MD, Badolato GM, Delaney M, McCarter R, et al. Racial and/or Ethnic and Socioeconomic Disparities of SARS-CoV-2 Infection Among Children. *Pediatrics*. 2020;146(4).

**Figure 1.** Participant flow diagram



**Table 1.** Characteristics of the study population

	Unmatched Cohort (n=49,455)					Propensity Score-Matched Cohort (n=13,030)				
	Asthma (n=6,515)		No Asthma (n=42,940)		SMD	Asthma (n = 6,515)		No Asthma (n = 6,515)		SMD
Median (IQR) age, years	11.0	(8.0, 14.0)	11.0	(7.0, 14.0)	0.065	11.0	(8.0, 14.0)	11.0	(8.0, 14.0)	0.007
Gender					0.156					0.013
Female	2767	42%	21562	50%		2767	42%	2725	42%	
Male	3748	58%	21378	50%		3748	58%	3790	58%	
Race/ethnicity					0.384					0.021
Hispanic	881	14%	10027	24%		881	14%	857	13%	
Non-Hispanic Black	3509	55%	15556	38%		3509	55%	3561	57%	
Non-Hispanic White	1425	22%	11954	28%		1425	22%	1400	22%	
Other racial minority groups	557	9%	3887	9%		557	9%	565	9%	
Insurance status					0.316					0.027
Private	2524	39%	17116	40%		2524	39%	2542	39%	
Public	3710	57%	20643	48%		3710	57%	3724	57%	
Self-pay	237	4%	4943	12%		237	4%	215	4%	
Neighborhood deprivation index					0.078					0.021
1-5	4139	66%	28843	69%		4139	66%	4198	66%	
6-10	2177	34%	13025	31%		2177	34%	2132	34%	
Well-child visit in the prior two years	4460	69%	22,432	52%	0.336	4460	69%	4481	69%	0.007
Median (IQR) number of encounters in prior year	2	(1, 4)	1.00	(0, 2)	0.272	2	(1, 4)	2.00	(1, 3)	0.058
Primary care physician in DUHS	6432	99%	41472	97%	0.142	6432	99%	6439	99%	0.010
Tested for SARS-CoV-2 by PCR	676	10%	2918	7%	0.128	676	10%	611	9%	0.033

SMD, standardized mean difference; IQR, interquartile range; DUHS, Duke University Health System

**Table 2.** Factors associated with SARS-CoV-2 testing in the overall study population

	<b>Tested (n=3,594)</b>		<b>Not Tested (n=45,861)</b>		<b>Relative Risk (95% CI)</b>	
Asthma status						
Children with asthma	676	19%	5,839	15%	1.39	(1.28 – 1.51)
Children without asthma	2,918	81%	40,022	85%	1.00	Ref
Median (IQR) age, years	11.0	(7.0, 15.0)	11.0	(7.0, 14.0)	1.02	(1.01 – 1.03)
Gender						
Female	1,872	52%	22,457	49%	1.15	(1.07 – 1.22)
Male	1,722	48%	23,404	51%	1.00	Ref
Race/ethnicity						
Hispanic	984	28%	9,924	22%	1.33	(1.20 – 1.48)
Non-Hispanic Black	1,218	35%	17,847	40%	0.82	(0.74 – 0.90)
Non-Hispanic White	1,000	29%	12,379	28%	1.00	Ref
Other racial minority groups	301	9%	4,143	9%	0.94	(0.82 – 1.07)
Insurance status						
Public	1,982	56%	22,371	49%	1.12	(1.03 – 1.21)
Private	1,336	38%	18,304	40%	1.00	Ref
Self-pay	241	7%	4,939	11%	0.74	(0.64 – 0.86)
Neighborhood deprivation index						
1-5	2,259	65%	30,723	69%	1.00	Ref
6-10	1,228	35%	13,974	31%	1.20	(1.11 – 1.30)
Well-child visit in the prior two years	2,441	68%	24,451	53%	1.58	(1.47 – 1.70)
Median (IQR) number of encounters in prior year	4	(2, 7)	1	(0, 2)	1.03	(1.03 – 1.03)
Primary care physician in DUHS	3,581	>99%	44,323	97%	6.70	(4.05 – 12.21)

CI, confidence interval; IQR, interquartile range; DUHS, Duke University Health System



**Table 3.** Factors associated with testing positive among children tested for SARS-CoV-2

	SARS-CoV-2-Positive (n=564)		SARS-CoV-2-Negative (n=3,030)		Relative Risk (95% CI)	
Asthma status						
Children with asthma	66	12%	610	20%	0.69	(0.53 – 0.90)
Children without asthma	498	88%	2420	80%	1.00	Ref
Median (IQR) age, years	11.0	(8.0, 15.0)	11.0	(7.0, 15.0)	1.02	(1.00 – 1.05)
Gender						
Female	292	52%	1,580	52%	0.97	(0.82 – 1.15)
Male	272	48%	1,450	48%	1.00	Ref
Race/ethnicity						
Hispanic	315	57%	669	23%	4.36	(3.02 – 6.44)
Non-Hispanic Black	144	26%	1,074	36%	1.90	(1.30 – 2.81)
Non-Hispanic White	41	8%	959	32%	1.00	Ref
Other racial minority groups	50	9%	251	9%	2.94	(1.91 – 4.55)
Insurance status						
Public	412	73%	1,570	52%	1.77	(1.34 – 2.37)
Private	78	14%	1,250	42%	1.00	Ref
Self-pay	71	13%	170	6%	1.92	(1.33 – 2.77)
Neighborhood deprivation index						
1-5	253	46%	2,006	68%	1.00	Ref
6-10	294	54%	934	32%	1.29	(1.08 – 1.54)
Well-child visit in the prior two years	350	62%	2,091	69%	1.12	(0.94 – 1.33)
Median (IQR) number of encounters in prior year	3	(2, 5)	4	(2, 8)	0.95	(0.93 – 0.97)
Primary care physician in DUHS	561	>99%	3,020	>99%	1.23	(0.47 – 4.97)

CI, confidence interval; IQR, interquartile range; DUHS, Duke University Health System

**Table 4.** Associations between asthma status and SARS-CoV-2 infection, propensity score-matched cohort

	<b>SARS-CoV-2 Infection</b>		<b>Adjusted RR (95% CI)</b>		<b>P</b>
<b>Primary analysis</b>					
Asthma (n=6,515)	66	9.8%	0.67	(0.49, 0.92)	0.01
No asthma (n=6,515)	98	16.0%	1.00	Ref	–
<b>Effect modification analyses</b>					
Inhaled corticosteroid prescription					
Yes (n=3,384)	30	8.3%	0.60	(0.38, 0.94)	0.03
No (n=3,131)	36	11.5%	0.75	(0.49, 1.15)	0.19
Comorbid atopic disease					
Yes (n=4,003)	37	8.0%	0.59	(0.39, 0.88)	0.01
No (n=2,512)	29	13.5%	0.83	(0.51, 1.35)	0.45

**Supplemental Table 1.** Diagnostic codes for asthma and atopic diseases

<b>Diagnosis</b>	<b>ICD-9</b>	<b>ICD-10</b>
Asthma	493.*	J45.*
Atopic diseases		
Allergic rhinitis	477.*	J30.*
Acute atopic conjunctivitis	372.05	H10.1*
Other chronic allergic conjunctivitis	372.14	H10.45
Personal history of allergy, other than to medicinal agents, presenting hazards to health	V15.0*	Z91.0*
Anaphylactic reaction due to unspecified food	995.6*	T78.*
Other adverse food reactions, not elsewhere classified	995.7	T78.*
Atopic dermatitis and related conditions	691.*	L20.*

**Supplemental Table 2.** Asthma prescription medications

<b>Category</b>	<b>Medication</b>
Rescue medications	Albuterol Dry Powder Inhaler [ProAir]
	Albuterol Inhalant Solution
	Albuterol Metered Dose Inhaler [ProAir, Proventil, Ventolin]
	Albuterol Oral Tablet
	Albuterol/ipratropium bromide Inhalant Solution [DuoNeb]
	Albuterol/ipratropium bromide Metered Dose Inhaler [Combivent]
	Ipratropium bromide Inhalant Solution [Atrovent]
	Ipratropium bromide Metered Dose Inhaler [Atrovent]
	Levalbuterol Inhalant Solution [Xopenex]
	Levalbuterol Metered Dose Inhaler [Xopenex]
ICS	Beclomethasone Dipropionate Metered Dose Inhaler [Qvar]
	Budesonide Dry Powder Inhaler [Pulmicort]
	Budesonide Inhalant Solution [Pulmicort]
	Ciclesonide Metered Dose Inhaler [Alvesco]
	Fluticasone furoate Dry Powder Inhaler [Arnuity Ellipta]
	Fluticasone propionate Dry Powder Inhaler [Flovent]
	Fluticasone propionate Metered Dose Inhaler [Flovent]
Mometasone furoate Dry Powder Inhaler [Asmanex]	
LTRA	Montelukast Oral Tablet [Singulair]
	Zileuton Oral Tablet [Zyflo]
LABA	Salmeterol inhalant product [Serevent]
LAMA	Tiotropium Metered Dose Inhaler [Spiriva]
Combination therapies	Budesonide / formoterol fumarate Metered Dose Inhaler [Symbicort]
	Fluticasone furoate / vilanterol Dry Powder Inhaler [Breo]
	Fluticasone propionate / salmeterol Metered Dose Inhaler [Advair]
	Fluticasone propionate / salmeterol Dry Powder Inhaler [Advair]
	Mometasone fumarate / formoterol fumarate Metered Dose Inhaler [Dulera]
Biologics	Omalizumab [Xolair]
	Mepolizumab [Nucala]

LTRA, leukotriene receptor antagonist; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent

**Supplemental Figure 1.** Distribution of propensity scores in matched cohort

